ArticleBritish journal of cancer1999
Role of thrombin receptor in breast cancer invasiveness.
Article in British journal of cancer, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 116 citations in OpenAlex.
- Comparative Glycoproteomic Analysis of Mouse 4T1 Breast Cancer Model.Current medicinal chemistry · 2025Article
- Article
- Impact of Fibrinogen, Fibrin Thrombi, and Thrombin on Cancer Cell Extravasation Using In Vitro Microvascular Networks.Advanced healthcare materials · 2023Article
- Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma?BMC cancer · 2022Article
- Piezo1 activation attenuates thrombin-induced blebbing in breast cancer cells.Journal of cell science · 2022Article
- Higher intra-tumoral expression of pro-coagulation genes is a predictor of angiogenesis, epithelial mesenchymal transition and worse patient survival in gastric cancer.American journal of cancer research · 2022Article
- Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2021Review
- Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Article
- Deciphering the Role of the Coagulation Cascade and Autophagy in Cancer-Related Thrombosis and Metastasis.Frontiers in oncology · 2020Review
- Endothelial barrier protective properties of low molecular weight heparin: A novel potential tool in the prevention of cancer metastasis?Research and practice in thrombosis and haemostasis · 2017Article
- Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients.Biomedical reports · 2016Article
- Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2.Oncogene · 2016Article
- Claudin-4 is required for vasculogenic mimicry formation in human breast cancer cells.Oncotarget · 2015Article
- Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation.Journal of cancer research and clinical oncology · 2015Article
- Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells.Molecular cancer · 2015Article
- Activation of blood coagulation in cancer: implications for tumour progression.Bioscience reports · 2013Review
- The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients.Molecular and cellular biochemistry · 2011Article
- Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer.The American journal of pathology · 2011Article
- Protease-activated receptors in cancer: A systematic review.Oncology letters · 2011Article
- Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells.Physical biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasion, the ability of an epithelial cancer cell to detach from and move through a basement membrane, is a central process in tumour metastasis. Two components of invasion are proteolysis of extracellular matrix and cellular movement through it. A potential promoter of these two processes is thrombin, the serine proteinase derived from the ubiquitous plasma protein prothrombin. Thrombin promotes the invasion of MDA-MB231 breast tumour cells (a highly aggressive cell line) in an in vitro assay. Invasion by MDA-MB436 and MCF-7 cells, less aggressive cell lines, is not promoted by thrombin. Thrombin, added to the cells, is a stimulator of cellular movement; fibroblast-conditioned medium is the chemotaxin. Thrombin-promoted invasion is inhibited by hirudin. Stimulation of invasion is a receptor-mediated process that is mimicked by a thrombin receptor-activating peptide. Thrombin has no effect on chemotaxis in vitro. Thrombin receptor is detectable on the surface of MDA-MB231 cells, but not on the other two cell lines. Introduction of oestrogen receptors into MDA-MB231 cells by transfection with pHEO had no effect on thrombin receptor expression, in the presence or absence of oestradiol. This paper demonstrates that thrombin increases invasion by the aggressive breast cancer cell line MDA-MB231 by a thrombin receptor-dependent mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.